The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole.
The influence of the vehicle on the release and permeation of fluconazole, a topical antifungal drug dissolved in Jojoba oil was evaluated. Series of Cutina lipogels (Cutina CPA [cetyl palmitate], CBS [mixture of glyceryl stearate, cetearyl alcohol, cetyl palmitate, and cocoglycerides], MD [glyceryl stearate], and GMS [glyceryl monostearate]) in different concentrations as well as gel microemulsion were prepared. In-vitro drug release in Sorensen's citrate buffer (pH 5.5) and permeation through the excised skin of hairless mice, using a modified Franz diffusion cell, were performed. The rheological behavior and the apparent viscosity values for different gel bases were measured before and after storage under freezing conditions at -4 degrees C and were taken as measures for stability of network structure. Candida albicans was used as a model fungus to evaluate the antifungal activity of the best formula achieved. The results of in vitro drug release and its percutaneous absorption showed that the highest values from gel microemulsion were assured. The rheological behavior of the prepared systems showed pseudoplastic (shear-thinning) flow indicating structural breakdown of the existing intermolecular interactions between polymeric chains. Moreover, the stability study revealed no significant difference between viscosity before and after storage for different formulae except for CPA Cutina lipogel (using analysis of variance [ANOVA] test at level of significance.05). The antifungal activity of fluconazole showed the widest zone of inhibition with gel microemulsion. The gel microemulsion is an excellent vehicle for fluconazole topical drug delivery.
El Laithy
H M
HM
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. khayatt@soficom.com.eg
El-Shaboury
K M F
KM
D000287:Administration, Topical; D000818:Animals; D000831:Animals, Newborn; D000935:Antifungal Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D001230:Aspergillus / Q000187:drug effects / Q000254:growth & development; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development; D003045:Coccidioides / Q000187:drug effects / Q000254:growth & development; D003454:Cryptococcus / Q000187:drug effects / Q000254:growth & development; D015194:Diffusion Chambers, Culture; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D004655:Emulsions / Q000737:chemistry; D015725:Fluconazole / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D005782:Gels / Q000737:chemistry*; D066298:In Vitro Techniques; D051379:Mice; D008812:Mice, Hairless; D008826:Microbial Sensitivity Tests; D012867:Skin / Q000737:chemistry / Q000378:metabolism
D000935:Antifungal Agents; D004655:Emulsions; D005782:Gels; D015725:Fluconazole